Overview Dividends

(MNKD) MannKind - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US56400P7069

Inhaled,Insulin,Diabetes,Respiratory

MNKD EPS (Earnings per Share)

EPS Growth (3Y CAGR): 268.07%
EPS Trend (3Y Correlation): 89.0%

MNKD Revenue

Revenue Growth (3Y CAGR): 34.89%
Revenue Trend (3Y Correlation): 94.9%

Risk via 10d forecast
Volatility	52.0%
Value at Risk 5%th	76.0%

Reward
Sharpe Ratio	-0.47
Alpha Jensen	-41.61

Character
Hurst Exponent	0.477
Beta	0.811

Drawdowns 3y
Max DD	54.03%
Mean DD	22.80%

Description: MNKD MannKind August 18, 2025

MannKind Corp (NASDAQ:MNKD) is a biotechnology company listed on the NASDAQ exchange, operating in the United States. The companys stock performance is characterized by a relatively high beta of 1.017, indicating a moderate level of volatility in relation to the overall market.

From a fundamental analysis perspective, MannKind Corp has a market capitalization of approximately $1.049 billion USD, with a price-to-earnings (P/E) ratio of 31.09 and a forward P/E ratio of 23.47. These metrics suggest that the companys stock is trading at a premium relative to its current earnings, but the forward P/E ratio indicates potential for earnings growth. The absence of Return on Equity (RoE) data may indicate that the company is not yet profitable or has negative equity.

Key economic drivers for MannKind Corp include the demand for its pharmaceutical products, particularly Afrezza, an inhaled insulin product used for the treatment of diabetes. The companys revenue growth and profitability are closely tied to the market adoption and sales performance of Afrezza. Key Performance Indicators (KPIs) to watch include revenue growth rate, gross margin, and operating expenses as a percentage of revenue.

To evaluate the investment potential of MannKind Corp, it is essential to analyze the companys financial statements, management team, and industry trends. A thorough analysis of the companys income statement, balance sheet, and cash flow statement can provide insights into its financial health, profitability, and cash generation capabilities. Additionally, assessing the competitive landscape, regulatory environment, and market trends in the biotechnology industry can help investors make informed decisions.

MNKD Stock Overview

Market Cap in USD	1,664m
Sub-Industry	Biotechnology
IPO / Inception	2004-07-28
Return 12m vs S&P 500	-36.1%
Analyst Rating	4.86 of 5

MNKD Dividends

Currently no dividends paid

MNKD Growth Ratios

CAGR	6.37%
CAGR/Max DD Calmar Ratio	0.12
CAGR/Mean DD Pain Ratio	0.28
Current Volume	3825.3k
Average Volume	3794.4k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (29.2m TTM) > 0 and > 6% of Revenue (6% = 18.8m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 79.58% (prev 95.64%; Δ -16.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 48.9m > Net Income 29.2m (YES >=105%, WARN >=100%)

Net Debt (98.6m) to EBITDA (74.2m) ratio: 1.33 <= 3.0 (WARN <= 3.5)

Current Ratio 3.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (311.6m) change vs 12m ago 9.46% (target <= -2.0% for YES)

Gross Margin 76.61% (prev 71.91%; Δ 4.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 65.45% (prev 57.56%; Δ 7.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.50 (EBITDA TTM 74.2m / Interest Expense TTM 31.6m) >= 6 (WARN >= 3)

Altman Z'' -23.17

(A) 0.50 = (Total Current Assets 358.8m - Total Current Liabilities 109.1m) / Total Assets 494.6m

(B) -6.43 = Retained Earnings (Balance) -3.18b / Total Assets 494.6m

warn (B) unusual magnitude: -6.43 — check mapping/units

(D) -5.89 = Book Value of Equity -3.18b / Total Liabilities 539.2m

Total Rating: -23.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.11

1. Piotroski 6.50pt = 1.50

2. FCF Yield 2.66% = 1.33

3. FCF Margin 13.83% = 3.46

4. Debt/Equity -5.07 = -2.50

5. Debt/Ebitda 1.33 = 1.26

7. RoE -49.33% = -2.50

8. Rev. Trend 94.87% = 7.12

9. EPS Trend 89.02% = 4.45

What is the price of MNKD shares?

As of November 14, 2025, the stock is trading at USD 5.07 with a total of 3,825,300 shares traded.
Over the past week, the price has changed by -11.05%, over one month by -0.59%, over three months by +35.92% and over the past year by -27.16%.

Is MannKind a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, MannKind is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 64.11 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNKD is around 4.53 USD . This means that MNKD is currently overvalued and has a potential downside of -10.65%.

Is MNKD a buy, sell or hold?

MannKind has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy MNKD.

Strong Buy: 6
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MNKD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	10.1	98.4%
Analysts Target Price	10.1	98.4%
ValueRay Target Price	5	-0.6%

MNKD Fundamental Data Overview November 12, 2025

Market Cap USD = 1.66b (1.66b USD * 1.0 USD.USD)
P/E Trailing = 54.2
P/E Forward = 77.5194
P/S = 5.304
P/EG = -0.23
Beta = 0.811
Revenue TTM = 313.8m USD
EBIT TTM = 47.3m USD
EBITDA TTM = 74.2m USD
Long Term Debt = 73.4m USD (from longTermDebt, last quarter)
Short Term Debt = 49.0m USD (from shortTermDebt, last quarter)
Debt = 226.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 98.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.63b USD (1.66b + Debt 226.0m - CCE 260.0m)
Interest Coverage Ratio = 1.50 (Ebit TTM 47.3m / Interest Expense TTM 31.6m)
FCF Yield = 2.66% (FCF TTM 43.4m / Enterprise Value 1.63b)
FCF Margin = 13.83% (FCF TTM 43.4m / Revenue TTM 313.8m)
Net Margin = 9.32% (Net Income TTM 29.2m / Revenue TTM 313.8m)
Gross Margin = 76.61% ((Revenue TTM 313.8m - Cost of Revenue TTM 73.4m) / Revenue TTM)
Gross Margin QoQ = 80.88% (prev 73.12%)
Tobins Q-Ratio = 3.30 (Enterprise Value 1.63b / Total Assets 494.6m)
Interest Expense / Debt = 3.25% (Interest Expense 7.33m / Debt 226.0m)
Taxrate = -2.62% (negative due to tax credits) (-204.0k / 7.78m)
NOPAT = 48.5m (EBIT 47.3m * (1 - -2.62%)) [negative tax rate / tax credits]
Current Ratio = 3.29 (Total Current Assets 358.8m / Total Current Liabilities 109.1m)
Debt / Equity = -5.07 (negative equity) (Debt 226.0m / totalStockholderEquity, last quarter -44.6m)
Debt / EBITDA = 1.33 (Net Debt 98.6m / EBITDA 74.2m)
Debt / FCF = 2.27 (Net Debt 98.6m / FCF TTM 43.4m)
Total Stockholder Equity = -59.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.91% (Net Income 29.2m / Total Assets 494.6m)
RoE = -49.33% (negative equity) (Net Income TTM 29.2m / Total Stockholder Equity -59.3m)
RoCE = 333.8% (EBIT 47.3m / Capital Employed (Equity -59.3m + L.T.Debt 73.4m))
RoIC = -1019 % (out of range, set to none) (NOPAT 48.5m / Invested Capital -4.76m)
WACC = 8.32% (E(1.66b)/V(1.89b) * Re(9.0%) + D(226.0m)/V(1.89b) * Rd(3.25%) * (1-Tc(-0.03)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.91%
[DCF Debug] Terminal Value 66.25% ; FCFE base≈37.5m ; Y1≈24.6m ; Y5≈11.3m
Fair Price DCF = 0.62 (DCF Value 189.5m / Shares Outstanding 307.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 89.02 | EPS CAGR: 268.1% | SUE: 2.72 | # QB: 1
Revenue Correlation: 94.87 | Revenue CAGR: 34.89% | SUE: 0.46 | # QB: 0

Additional Sources for MNKD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle